Short answer: By 2026, Humira (adalimumab) will be facing increased biosimilar competition in many markets, and the remaining patent protections will be more limited than in the early 2010s. AbbVie’s strategy to navigate the cliff hinges on protecting and growing other revenue streams, accelerating the company’s autoimmune/immunology pipeline, and expanding Humira’s lifecycle and global access where possible.
What “2026” typically implies for Humira from a patent standpoint
- U.S. and major markets: The strongest, composition-of-matter protection for adalimumab has eroded and many biosimilars were entering or ready to enter around 2023–2024. By 2026, the number of active, enforceable Humira-specific patents is expected to be small in key markets, leaving competition primarily on price and market access rather than patent exclusivity.
- Remaining protections: Any residual protection tends to come from formulation patents, method-of-use patents, data exclusivity, or country-specific patent extensions (and potentially settlement agreements with biosimilar developers). These can vary by jurisdiction, so the exact status in the EU, UK, Canada, or ROW may differ.
- Market consequence: Expect continued price pressure from biosimilars in major markets, with revenue risk still present in 2026 unless offset by growth in other products and indications.
AbbVie’s strategic levers to weather the cliff
- Build and defend a broad, high-growth portfolio beyond Humira
- Skyrizi (risankizumab) and Rinvoq (upadacitinib) are the backbone of AbbVie’s growth outside Humira. Expanding approved indications and robust patient access programs for these products help offset Humira declines.
- Continue to push new indications and real-world data for Skyrizi and Rinvoq to broaden their addressable market.
- Lifecycle management and optimization of Humira
- Where feasible, pursue formulation or delivery optimizations and expansion into additional, labelable indications to lengthen Humira’s revenue run.
- Global expansion and access
- Accelerate Humira-related income in regions where biosimilar entry is slower or later due to pricing, reimbursement, or regulatory timelines.
- Leverage patient support and value-based arrangements to maintain uptake in price-pressured markets.
- Pipeline and early-stage assets
- Invest in early- to mid-stage programs in autoimmune/inflammatory diseases and related therapeutic areas to diversify risk away from Humira alone.
- Seek partnerships or licensing deals that bolster the immunology portfolio or accelerate access to next-generation therapies.
- Cost discipline and capital allocation
- Optimize manufacturing scale and product mix to sustain margins as revenue shifts.
- Use capital to fund high-potential acquisitions, collaborations, or internal R&D that reinforce long-term growth beyond Humira.
- Competitive and regulatory intelligence
- Monitor biosimilar settlement dynamics, regulatory changes, and payer landscape to anticipate pricing and market access challenges.
- Track patent status region-by-region to inform timing of launches, settlements, or litigation strategies.
If you want, I can tailor this to a specific market (e.g., United States vs. EU vs. Japan) and provide:
- A region-by-region view of likely patent expiry timelines and biosimilar entry windows.
- A prioritized 2024–2026 action plan for AbbVie (which products to push, which regions to focus on, etc.).
- Key data points to watch (FDA/EMA approvals, new indications for Skyrizi/Rinvoq, major biosimilar settlements, and any updated patent rulings).
Would you like a regional timeline (US, EU, Canada, UK, etc.) and a brief on AbbVie’s current pipeline priorities for 2024–2026? If you have a specific region or a particular angle (investor briefing, competitive analysis, regulatory strategy), tell me and I’ll tailor it.